CLINICAL STUDIES
DURAL AUGMENTATION: PART I—EVALUATION
OF COLLAGEN MATRIX ALLOGRAFTS FOR DURAL
DEFECT AFTER CRANIOTOMY
Zachary N. Litvack, M.D.
Department of Neurological Surgery,
Oregon Health & Science University,
Portland, Oregon
G. Alexander West, M.D., Ph.D.
Colorado Brain and Spine Institute,
Englewood, Colorado
Johnny B. Delashaw, M.D.
Department of Neurological Surgery,
Oregon Health & Science University,
Portland, Oregon
Kim J. Burchiel, M.D.
Department of Neurological Surgery,
Oregon Health & Science University,
Portland, Oregon
Valerie C. Anderson, Ph.D., M.C.R.
Department of Neurological Surgery,
Oregon Health & Science University,
Portland, Oregon
Reprint requests:
Zachary N. Litvack, M.D.,
Department of Neurological Surgery CR-137,
Oregon Health & Science University,
3181 SW Sam Jackson Park Road,
Portland, OR 97239.
Email: litvackz@ohsu.edu
Received, November 12, 2008.
Accepted, June 5, 2009.
Copyright © 2009 by the
Congress of Neurological Surgeons
OBJECTIVE: Primary closure of the dura remains difficult in many neurosurgical cases.
One option for dural grafting is the collagen sponge, which is available in multiple
forms, namely, monolayer collagen and bilayer collagen. Our primary goal was to assess
differences in the incidence of postoperative cerebrospinal fluid (CSF) leak, including
fistula and pseudomeningocele, and postoperative infection between monolayer collagen and bilayer collagen grafts.
METHODS: A single-center retrospective analysis of 475 consecutive neurosurgical
procedures was performed. Primary endpoints were CSF leak and infection, adjusting
for the impact of additional nonautologous materials. Multivariate regression analysis
was used to identify predictors of postoperative CSF leak and infection.
RESULTS: The overall frequency of postoperative CSF leak was 6.7%. There was no significant difference in the incidence of CSF leak based on the type of collagen sponge
(monolayer versus bilayer) used (5.5% versus 7.5%, respectively; P ⫽ 0.38). The overall frequency of postoperative infection was 4.2%. There was no significant difference
in the incidence of infection between groups (4.9% versus 3.8%; P ⫽ 0.54). Bilayer
sponges were associated with a significantly lower incidence of CSF leak than monolayer sponges (odds ratio, 0.09; 95% confidence interval, 0.01–0.73).
CONCLUSION: Bilayer collagen sponges are associated with a reduction in postoperative CSF leak, notably in posterior fossa surgery. The need for additional non-native
materials is predictive of postoperative CSF leak, along with location and type of procedure. Intrinsic patient characteristics (e.g., age, diabetes, smoking) do not seem to
affect the efficacy of collagen sponge dural grafts.
KEY WORDS: Collagen sponge, Dural closure, Dural graft, Duraplasty
Neurosurgery 65:890–897, 2009
DOI: 10.1227/01.NEU.0000356970.22315.BC
F
ailure to repair native dura after neurological surgery remains a significant source of
morbidity for many neurosurgical procedures. Closure of the dura serves as a mechanical
and biological barrier to both the egress of cerebrospinal fluid (CSF) and the ingress of infectious organisms. In many cases, primary closure
remains difficult, if not impossible, because of
the inherent pathology or the insufficiency of
native dura. Since the first report of duraplasty
using natural latex in the late 19th century, surgeons and engineers have pursued alternatives
ABBREVIATIONS: BL, bilayer; CSF, cerebrospinal
fluid; ML, monolayer; OR, odds ratio; PEG, polyethylene glycol
890 | VOLUME 65 | NUMBER 5 | NOVEMBER 2009
www.neurosurgery-online.com
for dural substitution, including autograft, allograft, xenograft, and synthetics (1–8, 10, 14,
16–19, 21–25, 27–30, 32–34, 37). Despite decades
of research, the incidence of CSF leak (fistula or
pseudomeningocele) after craniotomy remains
as high as 10% (10, 13). In this report, we present
our outcomes and experiences with matrix grafts
manufactured from reconstituted type I bovine
collagen. This includes use of these grafts in combination with cranioplasty material and dural
sealants. In a subsequent report, we will present
our institutional experience with the effects of
dural sealants on postoperative dural integrity
and infection.
A single-center retrospective analysis of 475
consecutive neurosurgical procedures in which
www.neurosurgery-online.com
COLLAGEN MATRIX DURAL GRAFTS
3) spinal or transsphenoidal operation (5.2% and 0.8%, respectively); 4)
death within 24 hours of operation because of underlying causes
(0.6%); and 5) excessive number (n ⫽ 47) of previous operations (0.2%).
In total, 475 cases were evaluated.
Clinical Material and Methods
ML (DuraGen or DuraGen Plus) sponges or BL sponges (Suturable
DuraGen) were implanted in the patients at the attending surgeon’s
discretion and based on product availability. During the study period,
the first use of DuraGen Plus was July 2004, and the first use of the
suturable sponge was February 2005. Before availability of the
suturable product, the collagen sponge was used exclusively in an
onlay fashion, with edges overlapping the dural defect. The suturable
sponge was used in 1 of 2 fashions: as either an onlay or an inlay/
underlay. In the case of an inlay, the graft was sized larger than the
defect and then sutured to the dural edge with a running 4–0 braided
nylon suture to prevent migration. In addition to collagen sponge, foreign materials used (at the surgeons discretion) included bovine pericardial patch (Lyoplant; Aesculap, Inc., Center Valley, PA), calcium
phosphate cranioplasty (Norian CRS; Synthes, West Chester, PA), and
dural sealant, either fibrin glue (Tisseel; Baxter, Westlake Village, CA)
or polyethylene glycol (PEG) hydrogel (DuraSeal; Confluent Surgical,
Waltham, MA). Per our standard of care, calcium phosphate was
impregnated with vancomycin before implantation.
FIGURE 1. Study flow diagram. *, More than 40 previous cranial operations.
a collagen sponge was used during closure of nontrauma cranial
operations was performed. The primary goal was to compare the
incidence of postoperative CSF leak and infection between 2
types of commercially available collagen sponges. We hypothesized that the bilayer (BL) sponge would have a lower incidence
of CSF leak and infection compared with the monolayer (ML)
sponge. In secondary analyses, we also examined the impact of
nonautologous materials (e.g., biological glues, dural grafts, and
cranioplasty material) on the incidence of CSF leak and infection
when used in conjunction with collagen sponges. Finally, in an
effort to predict which patients are most likely to benefit from the
use of these products, we examined correlates of CSF leak and
infection in this large patient series.
PATIENTS AND METHODS
Patient Population
The study was performed at Oregon Health & Science University,
a quaternary care academic hospital, and was approved by its
Committee on Human Research. A retrospective search of surgical and
billing records between January 2004 and August 2006 identified 523
operations in 480 patients in which collagen duraplasty (DuraGen,
DuraGenPlus, or Suturable DuraGen; Integra LifeScience Corp.,
Plainsboro, NJ) was performed. We then confirmed use of a collagen
graft by reviewing the surgeon’s operative report, and the circulating
RN’s implant record. All patients were 18 years of age and older. Data
were collected using a double-entry method. A flow chart of case inclusion is presented in Figure 1. Cases were excluded for the following
reasons: 1) product was billed, but according to the operative record,
not implanted, (0.6%); 2) incomplete records or loss to follow-up (1.9%);
NEUROSURGERY
Statistical Methods
Two exposure groups were defined, ML (DuraGen and DuraGen
Plus) or BL (Suturable DuraGen), with secondary exposure to dural
sealant (Tisseel or DuraSeal) or cranioplasty (Norian CRS). The ML
products were grouped together based on the assumption that the
manufacturing differences between the 2 products do not significantly
affect in vivo performance. Primary endpoints were defined as CSF
leak (including fistula and clinically diagnosed pseudomeningocele)
and infection (including wound infections, abscess, and meningitis).
For the purpose of our analyses, both fistula and pseudomeningocele
were defined as CSF leak because, in our opinion, either outcome represents a primary failure of dural closure. Pseudomeningocele evident
solely on postoperative imaging, which did not come to the patient’s or
surgeon’s attention on postoperative examination, was not included as
a complication. Infections were classified according to Centers for
Disease Control and Prevention criteria for surgical site infection,
although we use the term deep instead of organ space (15).
Pearson’s χ2 test and analysis of variance were used to compare
characteristics of exposure groups. Association of categorical exposure(s) and outcome(s) was assessed using Pearson’s χ2 test or, when
expected counts were small, Fisher’s exact test. The rank-sum test was
used to determine the significance of differences in event curves. Odds
ratios (ORs) are reported with 95% confidence intervals. All P values
were calculated at the 0.05 significance level in 2-sided tests.
The univariate relationship between independent variables and
outcome(s) was assessed using crude ORs from simple logistic
regression. Because of sample size constraints, some categorical variables were compressed to binary form. Multivariate logistic regression models of CSF leak and infection status were constructed using
backward, stepwise methods. In each case, effects were allowed to
enter the model if the univariate association was significant at a P
value of 0.2 or less. Interaction effects between significant predictors
and outcome(s) were explored. All analyses were conducted using
SPSS (version 14; SPSS Inc., Chicago IL) and STATA (version 9;
StataCorp, College Station, TX).
VOLUME 65 | NUMBER 5 | NOVEMBER 2009 | 891
LITVACK ET AL.
TABLE 1. Baseline Characteristics of Cohort by Exposurea
Monolayer
(n ⴝ 292)
Bilayer
(n ⴝ 183)
P value
Age, y
52.2 ⫾ 16.2
53.4 ⫾ 15.0
NS
Sex, % male
126 (43)
Characteristics
70 (38)
Smoking status
Never
158 (54.1)
107 (58.5)
Current
75 (25.9)
41 (22.4)
Previous
59 (20.0)
35 (19.1)
28.4 ⫾ 6.9
29.0 ⫾ 6.2
BMI, kg/m2
Diabetes
269 (92.1)
Type 1
1 (0.4)
1 (0.6)
Type 2
22 (7.5)
22 (12.0)
Length of operation, min
NS
NS
None
Previous CNS surgery
NS
NS
101 (35)
160 (87.4)
66 (36)
NS
175.3 ⫾ 81.5
145.3 ⫾ 79.0
⬍0.005
203 ⫾ 256
116 ⫾ 149
⬍0.005
Length of follow-up, d
a
NS, not significant; BMI, body mass index; CNS, central nervous system. Mean ⫾
SD or number (%).
RESULTS
Baseline Characteristics
ML collagen (DuraGen or DuraGen Plus) was used in 61.5%
(292/475) of the cases. Groups were well matched with respect
to important characteristics, with the exception of surgery
duration and length of follow-up (Table 1). The length of
follow-up in the ML group was significantly longer than that in
the BL group (203 versus 116 days, respectively; P ⬍ 0.001). The
length of operation was significantly longer in the ML group
compared with the BL group (175 minutes versus 144 minutes,
respectively; P ⬍ 0.001). This difference in operation length
persisted as a strong trend after stratifying by convexity versus
cranial base approaches (P ⫽ 0.08).
Overall, 325 supratentorial (68.4%) and 150 infratentorial
(31.6%) operations were evaluated. The 3 most common surgical approaches were frontal craniotomy (41%), suboccipital/retrosigmoid craniotomy (27%), and temporal craniotomy
(12%). The most common indication for surgery was tumor
resection (221 of 475; 47%) (Fig. 2).
Causes of Death
Overall mortality during the follow-up period was 12.3%
(36/292) in the ML group and 9.8% (18/183) in the BL group
(P ⫽ 0.46). Two deaths (0.4%) are particularly notable as complications of surgery and potentially the implantation of a collagen
sponge. One death was caused by fatal meningitis that developed secondary to a persistent postoperative CSF leak, despite
diversion (lumbar drain) and operative revision. This leak
developed after a combined craniofacial resection of a nasopha-
892 | VOLUME 65 | NUMBER 5 | NOVEMBER 2009
FIGURE 2. Case distribution. Vascular category includes emergent neurosurgical cases such as ruptured
aneurysm or nontraumatic hematoma evacuation.
Congenital/Acquired category includes anatomic defects
(congenital or iatrogenic) producing a cerebrospinal
fluid fistula or pseudomeningocele requiring repair.
ryngeal adenocarcinoma that had eroded from the sinuses,
through the orbit, into the anterior cranial fossa. In this case, BL
collagen was used to reconstruct the dura of the cranial base of
the anterior fossa and was tacked in place with sutures without
obtaining a watertight closure. This was the third recurrence of
the tumor, and the patient had previously received radiation to
the field, precluding the use of a vascularized pericranial graft.
A second notable death was caused by septic multisystem organ
failure that seems to have originated as an orbital cellulitis after
bifrontal craniotomy for olfactory groove meningioma. After
resection of the meningioma, a 2-layered reconstruction of the
floor of the anterior fossa was performed, consisting of BL collagen and a vascularized pericranial graft.
CSF Leak
The overall frequency of postoperative CSF leak was 6.7%
(32 of 475). This included 23 CSF fistulae and 9 pseudo meningoceles. As described above, we consider these complications synonymous, although their management is different;
both outcomes represent a failure of dural integrity. Although
we noted a somewhat lower incidence of CSF leak in the BL
group than the ML group (5.5% versus 7.5%, respectively), this
difference was not significant (P ⫽ 0.4) (Fig. 3A; Table 3).
However, we did note a significantly higher incidence of CSF
leak in infratentorial (11.3%) versus supratentorial (4.6%) operations (odds ratio [OR], 2.3; 95% CI, 1.3–5.5). There were no significant differences in the incidence of leak between patients
who had never had a previous operation and patients undergoing a reoperation (6.8% versus 6.6%, respectively; P ⫽ 0.9).
Furthermore, the lack of evidence of a significant difference
based on reoperation status held when stratifying by type of
graft implanted or the addition of dural sealant.
Three of the pseudomeningoceles were managed expectantly
and resolved without further intervention. Of the remaining
CSF leaks, 34% (11 of 32) were managed with operative explo-
www.neurosurgery-online.com
COLLAGEN MATRIX DURAL GRAFTS
A
TABLE 2. Organisms isolated in cases of postoperative infection
with the use of a collagen sponge (n ⴝ 20)a
Isolate
% (no.)
Staphylococcus aureus
55.0 (11)
Methicillin-resistant S. aureus
15.0 (3)
Polymicrobiala
5.0 (1)
Serratia marcescens
5.0 (1)
Culture negative
a
20.0 (4)
Propionibacterium acnes, Escherichia coli, Lactobacillus, Enterobacter cloacae.
TABLE 3. Incidence of postoperative complications with the use
of a collagen spongea
% (no.)
P value
Monolayer
7.5 (22)
NS
Bilayer
5.5 (10)
Complication
CSF leak
B
Infection
a
FIGURE 3. Cumulative risk of postoperative complication with collagen
sponge duraplasty. A, 200-day cumulative event curve for the development
of a cerebrospinal fluid (CSF) leak with implantation of monolayer versus
bilayer collagen. B, 200-day cumulative event curve for the development
of infection. Differences are nonsignificant (P ⫽ 0.4 and P ⫽ 0.6, respectively). Postop, postoperatively.
ration/revision, 16% (5 of 32) with lumboperitoneal shunting,
9% (3 of 32) with ventriculoperitoneal shunting, and the
remaining 31% (10 of 32) with lumbar drainage without operative wound revision.
Infection
The overall frequency of postoperative infection was 4.2%
(20 of 475). There were 14 superficial surgical wound infections
NEUROSURGERY
Monolayer
3.8 (11)
Bilayer
4.9 (9)
NS
CSF, cerebrospinal fluid; NS, not significant.
and 6 deep (i.e., meningitis or abscess) infections. Two cases of
meningitis were preceded by the development of a CSF fistula
with a subsequent superinfection. There was no significant difference in the incidence of infection in the BL and ML groups
(4.9% versus 3.8%, respectively; P ⫽ 0.5) (Fig. 3B; Table 3). The
most common isolates from infections were Staphylococcus
aureus in 11 cases (78.6%), an additional 3 cases of methicillinresistant S. aureus, 1 case of Serratia marcescens, 1 case of
Propionibacterium acnes, and 1 polymicrobial infection that
included P. acnes, Escherichia coli, Lactobacillus, and Enterobacter
cloacae (Table 2).
Despite the significant difference in CSF leak between the
supratentorial and infratentorial cases, there was no significant
difference in infection rates (4.9% versus 2.7%, respectively;
P ⫽ 0.3). Among all cases of postoperative infection, there was
a 65% reoperation rate (i.e., operative débridement, removal of
bone flap, and/or removal of implant).
Additional Complications
There were 2 cases of aseptic meningitis in the cohort. In
both cases, implantation of collagen graft was performed as
part of a reoperation to repair an existing CSF leak. In both
cases, patients had symptoms (headache, nausea, photophobia) preoperatively. Because we were unable to establish a clear
temporal association between implantation and then development of aseptic meningitis, we omitted these complications
from analysis. There were no cases of postoperative seizures
after implantation of the collagen graft.
VOLUME 65 | NUMBER 5 | NOVEMBER 2009 | 893
LITVACK ET AL.
A
TABLE 4. Incidence of postoperative complications with the
combined use of a collagen sponge and dural sealanta
% (no.)
P value
No sealant
4.4 (14)
0.01
Fibrin glue
10.8 (11)
PEG hydrogel
13.2 (7)
Complication
CSF leak
Infection
No sealant
5.6 (18)
Fibrin glue
0 (0)
PEG hydrogel
a
B
FIGURE 4. Cumulative risk of postoperative complications when combining collagen sponge with dural sealant. A, 200-day cumulative event
curve for the development of a cerebrospinal fluid (CSF) leak with implantation of no sealant, fibrin glue, or polyethylene glycol (PEG) hydrogel. B,
200-day cumulative event curve for the development of infection. There is
a significant increase in postoperative leaks when sealants are applied, but
no significant change in postoperative infection (P ⫽ 0.012 and P ⫽ 0.06,
respectively). Postop, postoperatively.
Effects of Nonautologous Materials
In approximately 33% of cases (155 of 475), collagen sponge
(either ML or BL) was used in combination with a gel sealant
(fibrin glue or PEG hydrogel) in an attempt to achieve a watertight duraplasty. There was no significant difference in the
894 | VOLUME 65 | NUMBER 5 | NOVEMBER 2009
0.05
3.8 (2)
CSF, cerebrospinal fluid; PEG, polyethylene glycol.
prevalence of sealant use between the ML and BL groups
(35.3% versus 28.4; P ⫽ 0.1), which held true after stratifying by
type of operation (P ⫽ 0.2). Fibrin glue was used in the majority (66%) of these cases, most commonly with ML collagen. In
contrast, PEG hydrogel was most commonly used in combination with BL collagen.
Postoperative CSF leak was significantly more frequent in
cases in which sealant was applied than in cases in which
sealant was not used (11.6% versus 4.4%, P ⫽ 0.01). There was
no significant association between incidence of leak and type of
sealant used (Fig.4A; Table 4).
The overall incidence of postoperative infection was significantly lower when sealant was applied than when it was not
(1.2% versus 5.6%; P ⫽ 0.02). There were 2 infections in the
sealant group, both of which were associated with use of PEG
hydrogel. There were no postoperative infections with fibrin
glue use. The small number of patients in whom an infection
developed after application of sealant made statistical tests of
differences between sealants inappropriate (Fig. 4B; Table 4).
Among all cases, approximately 31% (147 of 475) required
calcium phosphate cranioplasty for repair of a calvarial defect
after implantation of a collagen sponge. The overall incidence
of CSF leak in this group was 11.5% (17 of 147), significantly
greater than the 4.6% rate of CSF leak seen when no cranioplasty was performed (P ⫽ 0.02). There was no significant difference in rates of infection with or without cranioplasty (2.0%
versus 5.2%; P ⫽ 0.3) (Table 5).
Early in our institutional experience, collagen sponge was
used in an onlay fashion to cover the suture line between the
dura and a bovine pericardial patch graft. Post hoc subgroup
analysis revealed 38 cases in which ML collagen was combined
with bovine pericardium. There was no significant difference
between the incidence of CSF leak in these cases compared
with those in which ML collagen was used alone (12.2% versus
6.2%). These analyses also suggest a lower incidence of CSF
leak when BL collagen was used alone compared with the combination of ML and pericardium (5.6% versus 13.2%; P ⫽ 0.15).
There was no significant difference in rates of postoperative
infection with ML and pericardium versus BL collagen alone.
www.neurosurgery-online.com
COLLAGEN MATRIX DURAL GRAFTS
TABLE 5. Incidence of postoperative complications with the
combined use of a collagen sponge and cranioplastya
Complication
% (no.)
P value
4.6 (15)
0.02
CSF leak
No cranioplasty
Calcium phosphate
11.5 (17)
Infection
No cranioplasty
5.2 (17)
Calcium phosphate
a
NS
2 (3)
CSF, cerebrospinal fluid; NS, not significant.
TABLE 6. Significant multivariate predictors of outcome after collagen graft usea
a
Operative site
Predictor
Odds ratio
(95% CI)
P value
CSF leak
Supratentorial
Infratentorial
Sealant use (any)
Bilayer collagen
4.06 (1.4–11.7)
0.09 (0.01–0.7)
0.009
0.03
Infection
All
Sealant use (any)
0.2 (0.05–1.0)
0.05
CI, confidence interval; CSF, cerebrospinal fluid.
Predictors of Performance for Collagen Sponge Duraplasty
Multivariate regression models were constructed to identify
potential risk factors for the development of a CSF leak or postoperative CSF infection. Because of significant confounding,
separate models were developed for CSF leak in the supratentorial and infratentorial groups.
In the supratentorial group, use of any sealant (PEG hydrogel or fibrin glue) significantly increased the risk of the development of a postoperative CSF leak (OR, 4.1; 95% CI, 1.4–11.7).
Among infratentorial cases, the type of collagen sponge, but
not the use of sealant, was a significant predictor of the development of a postoperative CSF leak. Specifically, use of BL collagen was associated with a significantly lower incidence of
CSF leak (OR, 0.09; 95% CI, 0.01–0.7).
With respect to multivariate analysis of complication development, we found that application of sealant was associated
with a reduced risk of infection (OR, 0.2; 95% CI, 0.05–0.9).
Although the number of adverse (infectious) outcomes in the
sealant subgroup was too small to determine an association
with a particular type of sealant, it is notable that there were no
infections associated with use of fibrin glue (Table 6).
DISCUSSION
Use of non-native material to restore dural integrity after
cranial surgery is a calculated risk, balancing the benefit of
immediate restoration of dural integrity with the risk of a foreign graft. In the case of dural substitutes, the specific risks
include graft failure (i.e., development of a CSF fistula or
NEUROSURGERY
pseudomeningocele), infection, foreign body reaction, graft
rejection, allergic reaction, adhesions, and even delayed hemorrhage (9, 12, 23, 26, 35). Working with allograft, nonhuman
xenograft, and, most recently, synthetics, a significant amount
of research effort has been spent on nonautologous materials to
meet the needs of a dural replacement (1–8, 10, 14, 16–19, 21–25,
27–30, 32–34, 37).
There are at least 5 goals that should be met when engineering a dural substitute. First, the implant should serve to temporarily or permanently assume the function of the native tissue that it replaces (in this case, separating and sealing the
subdural compartment from the epidural space). Second, the
implant should induce host cells to differentiate and repair/
replace those lost during tissue resection (i.e., meningothelial
induction). Third, the implant should facilitate infiltration and
implantation of such cells (i.e., meningothelial conduction).
This characteristic is a direct function of the 3-dimensional
structure of the graft. Fourth, if possible, the implant should
include cellular components capable of regenerating the native
tissue (i.e., meningotheliogenesis). Fifth, one must take into
consideration surgical handling of the material. What surgeons
consider handling falls into 2 characteristics of the graft: ductility, the ability to conform to a surgical defect without deforming the surrounding tissues, and tensile strength, which is
inversely proportional to the density of the graft and translates
to the ability of the graft to hold suture under tension. Some of
these characteristics are mutually exclusive. For example, ductility and conductivity tend to come at the expense of tensile
strength (37).
Purely synthetic absorbable dural grafts (i.e., polyglactin),
which are engineered to be conductive and/or inductive, often
induce a vigorous inflammatory reaction that inhibits wound
healing and increases the risk of wound infection (11, 21, 23). In
contrast, nonabsorbable grafts are neither inductive nor conductive and act only as a mechanical barrier. Unlike absorbable
grafts, they heal primarily by encapsulation with a neomembrane, which forms in continuity with the cut edge of the dura.
Although a nonabsorbable graft may rapidly assume the barrier function of dura, its mechanical stability under tension
comes at the cost of pliability and conductivity. Because of
neomembranous healing, such grafts do not permit restoration
of native tissues over time.
One dural substitute that has been proven safe and effective
in both animal and clinical studies is the acellular dural grafts
derived from type I collagen. This 3-dimensional matrix of
collagen fibers acts as a scaffold for the healing of a dural tear
(18, 21, 37). Such matrix grafts have the advantage of direct
absorption of CSF, which may leak through a suture line,
decreased meningocerebral adhesions at the site of surgery,
and direct hemostatic effect with no apparent increase in postoperative infection (7). In our opinion, their principal advantage is that the structure allows both fibroblast migration and
neovascularization, setting up a reaction that allows the
implant to be replaced by native tissue within 2 to 3 months
(20, 31). Although they are not impermeable, the collagen
grafts are sufficient until native tissues are restored (21).
VOLUME 65 | NUMBER 5 | NOVEMBER 2009 | 895
LITVACK ET AL.
In this retrospective study, we compared homogeneous ML
collagen graft with a more recently developed BL collagen
graft. The BL sponge was approved as a “substantially equivalent design” to previous collagen matrix dural grafts without
clinical demonstration of equivalence (or lack thereof) to previous implants (36). Thus, we believed that a large retrospective cohort study was a reasonable design with which to examine the association of this newer graft with CSF leak and
infection. Furthermore, this cohort provided the opportunity
to examine the common practice of simultaneous implantation
of a sponge with other materials focusing on potential interactions between implants.
Our overall incidence of postoperative CSF leak was 6.7%,
well within the reported range (10, 13, 31). We found that fistulae developed in a smaller proportion of the patients receiving
BL collagen duraplasty and that this difference was significant
when performing procedures in the posterior fossa. It is likely
that the ability to hold a suture under tension allows the surgeon to better approximate the graft to the defect in the face of
increased hydrostatic pressure, even when only a few tacking
sutures are placed. When closing dura in the posterior fossa,
the data suggest that BL collagen is at least as effective as a nonabsorbable patch graft combined with a sponge over the suture
line. It may be that the mutually exclusive healing pathways for
these 2 types of grafts (encapsulation versus incorporation)
result in diminished efficacy when the 2 types of dural grafts
are combined.
With regard to the common practice of combining sponges
with other foreign material during closure, our findings suggest that there may be an increased risk of CSF leak in the
supratentorial space when a sealant and/or cranioplasty is
used in combination with collagen sponge. At this point, the
reason for this is not entirely clear. It may be that implantation of multiple products for dural closure represents the surgeons’ recognition of a situation with an inherently higher
risk of postoperative CSF leak. Conversely, the use of a
sealant may reduce the efficacy of the graft over time, likely
by impairing conductivity, which would lead to graft decay
without replacement by native tissue. Although these are
undoubtedly important findings, conclusions related to differences between sealants and/or cranioplasty will require
further study.
Additionally, in multivariate modeling predictors of leak or
infection, we found that intrinsic patient characteristics such as
nicotine exposure (smoking), diabetes, and patient age were
not significant factors. Surgeons should not hesitate to implant
a graft in procedures performed in the elderly, those with diabetes, or smokers; the advantage of dural closure seems to outweigh the risks of a foreign body implant in patients with
impaired wound healing.
CONCLUSION
This study examined our institutional experience with the
safety and efficacy of type I collagen sponges for duraplasty.
Compared with ML sponges, BL collagen sponges are associ-
896 | VOLUME 65 | NUMBER 5 | NOVEMBER 2009
ated with a reduction in postoperative CSF leak (fistula or
pseudomeningocele), especially in posterior fossa surgery.
There is no increased association with infection when implanting the BL sponge, and it can be safely combined with other
non-native closure materials. Under most circumstances, the BL
sponge provides sufficient restoration of dural integrity and
requires significantly less operative time to implant.
Patients who require additional nonautologous materials
to effect closure of the craniotomy site, such as dural sealants
and cranioplasty materials, are at increased risk of postoperative CSF leak. No conclusions should be drawn regarding
causality, merely that there is a strong association between
the use of multiple products and the development of a postoperative leak. Nonetheless, such patients should be counseled regarding their risks of CSF leak and the steps that may
be taken to manage it. In the next report, we will further
examine our institutional experience with fibrin glue and PEG
hydrogel as dural sealants.
Disclosure
The authors have no personal financial or institutional interest in any of the
drugs, materials, or devices described in this article.
REFERENCES
1. Berjano R, Vinas FC, Dujovny M: A review of dural substitutes used in neurosurgery. Crit Rev Neurosurg 9:217–222, 1999.
2. Biroli F, Fusco M, Bani GG, Signorelli A, Esposito F, de Divitiis O, Cappabianca
P, Cavallo LM: Novel equine collagen-only dural substitute. Neurosurgery 62
[Suppl 1]:273–274, 2008.
3. Boop FA, Chadduck WM: Silastic duraplasty in pediatric patients. Neurosurgery
29:785–788, 1991.
4. Caroli E, Rocchi G, Salvati M, Delfini R: Duraplasty: Our current experience.
Surg Neurol 61:55–59, 2004.
5. Cobb MA, Badylak SF, Janas W, Boop FA: Histology after dural grafting with
small intestinal submucosa. Surg Neurol 46:389–394, 1996.
6. Costantino PD, Wolpoe ME, Govindaraj S, Chaplin JM, Sen C, Cohen M,
Gnoy A: Human dural replacement with acellular dermis: Clinical results and
a review of the literature. Head Neck 22:765–771, 2000.
7. Danish SF, Samdani A, Hanna A, Storm P, Sutton L: Experience with acellular human dura and bovine collagen matrix for duraplasty after posterior
fossa decompression for Chiari malformations. J Neurosurg 104:16–20, 2006.
8. Filippi R, Schwarz M, Voth D, Reisch R, Grunert P, Perneczky A: Bovine pericardium for duraplasty: Clinical results in 32 patients. Neurosurg Rev
24:103–107, 2001.
9. Gomez H, Little JR: Spinal cord compression: A complication of siliconecoated Dacron dural grafts. Report of two cases. Neurosurgery 24:115–118,
1989.
10. Grotenhuis JA: Costs of postoperative cerebrospinal fluid leakage: 1-year,
retrospective analysis of 412 consecutive nontrauma cases. Surg Neurol
64:490–494, 2005.
11. Gudmundsson G, Søgaard I: Complications to the use of vicryl-collagen dural
substitute. Acta Neurochir (Wien) 132:145–147, 1995.
12. Islam S, Ogane K, Ohkuma H, Suzuki S: Usefulness of acellular dermal graft
as a dural substitute in experimental model. Surg Neurol 61:297–303, 2004.
13. Kumar A, Maartens NF, Kaye AH: Evaluation of the use of BioGlue((R)) in
neurosurgical procedures. J Clin Neurosci 10:661–664, 2003.
14. Maher CO, Anderson RE, McClelland RL, Link MJ: Evaluation of a novel
propylene oxide-treated collagen material as a dural substitute. J Neurosurg
99:1070–1076, 2003.
15. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR: Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices
Advisory Committee. Infect Control Hosp Epidemiol 20:250–280, 1999.
www.neurosurgery-online.com
COLLAGEN MATRIX DURAL GRAFTS
16. Mason MS, Raaf J: Homologous dura mater grafts: An experimental study
and clinical evaluation. Ann Surg 153:423–432, 1961.
17. Messing-Jünger AM, Ibáñez J, Calbucci F, Choux M, Lena G, Mohsenipour I,
Van Calenbergh F: Effectiveness and handling characteristics of a threelayer polymer dura substitute: A prospective multicenter clinical study.
J Neurosurg 105:853–858, 2006.
18. Narotam PK, José S, Nathoo N, Taylon C, Vora Y: Collagen matrix (DuraGen)
in dural repair: Analysis of a new modified technique. Spine 29:2861–2869,
2004.
19. Narotam PK, Reddy K, Fewer D, Qiao F, Nathoo N: Collagen matrix
duraplasty for cranial and spinal surgery: A clinical and imaging study.
J Neurosurg 106:45–51, 2007.
20. Narotam PK, Van Dellen JR, Bhoola K, Raidoo D: Experimental evaluation of
collagen sponge as a dural graft. Br J Neurosurg 7:635–641, 1993.
21. Narotam PK, van Dellen JR, Bhoola KD: A clinicopathological study of collagen sponge as a dural graft in neurosurgery. J Neurosurg 82:406–412, 1995.
22. Parízek J, Mĕricka P: Duraplasty with pretreated freeze-dried sterilized
human dura mater. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove
33:135–143, 1990.
23. Parízek J, Mĕricka P, Husek Z, Suba P, Spacek J, Nĕmecek S, Nĕmecková J,
Sercl M, Eliás P: Detailed evaluation of 2959 allogeneic and xenogeneic dense
connective tissue grafts (fascia lata, pericardium, and dura mater) used in the
course of 20 years for duraplasty in neurosurgery. Acta Neurochir (Wien)
139:827–838, 1997.
24. Parízek J, Mĕricka P, Spacek J, Nĕmecek S, Eliás P, Sercl M: Xenogeneic pericardium as a dural substitute in reconstruction of suboccipital dura mater in
children. J Neurosurg 70:905–909, 1989.
25. Parízek J, Sercl M, Michl A, Mĕricka P, Nĕmecek S, Nĕmecková J, Jakubec J:
Posterior fossa duraplasty in children: Remarks on surgery and clinical and
CT follow-up. Childs Nerv Syst 10:444–449, 1994.
26. Penfield W: Meningocerebral adhesions. A histological study of the results of
cerebral incisions and cranioplasty. Surg Gynecol Obstet 39:803–810, 1924.
27. Reyes-Moreno I, Verheggen R: Time-sparing and effective procedure for dural
closure in the posterior fossa using a vicryl mesh (Ethisorb). Neurocirugia
(Astur) 17:527–531, 2006.
28. Sakas DE, Charnvises K, Borges LF, Zervas NT: Biologically inert synthetic
dural substitutes. Appraisal of a medical-grade aliphatic polyurethane and a
polysiloxane-carbonate block copolymer. J Neurosurg 73:936–941, 1990.
29. Shimizu S, Koizumi H, Kurita M, Utsuki S, Oka H, Fujii K: Duraplasty in the
posterior fossa using a boat-shaped sheet of expanded polytetrafluoroethylene. Neurol Med Chir (Tokyo) 47:379–381, 2007.
30. Stancić MF, Nozica E, Penezić L: Cerebrospinal fluid seepage through
polyglactin 910 dura substitute manifested as spinal extradural collection of
fluid. Croat Med J 41:210–212, 2000.
31. Stendel R, Danne M, Fiss I, Klein I, Schilling A, Hammersen S, Pietilae T,
Jänisch W, Hopfenmüller W: Efficacy and safety of a collagen matrix for cranial and spinal dural reconstruction using different fixation techniques.
J Neurosurg 109:215–221, 2008.
NEUROSURGERY
32. Tachibana E, Saito K, Fukuta K, Yoshida J: Evaluation of the healing process
after dural reconstruction achieved using a free fascial graft. J Neurosurg
96:280–286, 2002.
33. Tubbs RS, Wellons JC 3rd, Blount JP, Oakes WJ: Posterior atlantooccipital
membrane for duraplasty. Technical note. J Neurosurg 97:266–268, 2002.
34. Vanaclocha V, Saiz-Sapena N: Duraplasty with freeze-dried cadaveric dura
versus occipital pericranium for Chiari type I malformation: Comparative
study. Acta Neurochir (Wien) 139:112–119, 1997.
35. Warren WL, Medary MB, Dureza CD, Bellotte JB, Flannagan PP, Oh MY,
Fukushima T: Dural repair using acellular human dermis: Experience with
200 cases: Technique assessment. Neurosurgery 46:1391–1396, 2000.
36. Witten C, Provost M: 510(K) Summary—DuraGen II Dural Regeneration
Matrix (K043427). Rockville, MD, Division of General Restorative and
Neurological Devices, Center for Devices and Radiologic Health, Food and
Drug Administration, 2005.
37. Zerris VA, James KS, Roberts JB, Bell E, Heilman CB: Repair of the dura mater
with processed collagen devices. J Biomed Mater Res B Appl Biomater
83:580–588, 2007.
Acknowledgments
This study was made possible through institutional research grants from the
National Center for Research Resources, National Institutes of Health Roadmap
for Medical Research (UL1 RR024140) and Integra LifeSciences Corporation,
Plainsboro, NJ. The authors are grateful to Shirley McCartney, Ph.D., for assistance
with preparation of this submission; Andrew Rekito, M.S., for assistance with
preparation of figures; and Melanie Hart, B.S., for assistance with data abstraction.
COMMENTS
L
itvack et al. present a complex retrospective review of a large series
of patients. As one might expect, when a large group of patients is
treated by multiple surgeons, it may be difficult to reach conclusions
about cause and effect. For example, as the authors note, why was the
risk of cerebrospinal fluid leak increased in patients who received dural
sealants and/or cranioplasty in addition to collagen sponges for dural
closure? It is likely that such patients were recognized during surgery
to have a higher risk of cerebrospinal fluid leak, and, thus, extra steps
were taken by the surgeon to try to prevent postoperative cerebrospinal
fluid leakage. A retrospective review cannot provide definitive answers
to these questions. Nevertheless, the descriptive data in this article and
the thoughtful Discussion should be of interest to all neurosurgeons.
Susanna Girocco
Alex B. Valadka
Houston, Texas
VOLUME 65 | NUMBER 5 | NOVEMBER 2009 | 897